Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03628183 · ClinicalTrials.gov registry record · NA
Tolerance of Infants Fed a Hydrolysate Formula
A NA study, sponsored by Abbott Nutrition.
- Completed
- Registry status
- NA
- Development phase
- 51
- Enrollment target
NCT03628183: Completed NA study, sponsored by Abbott Nutrition.
NCT03628183 is a NA study that has completed, run by Abbott Nutrition. The registered enrollment target is 51 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03628183, a NA study, has completed, sponsored by Abbott Nutrition.
- COMPLETED
- Registry status
- NA
- Development phase
- 51 participants
- Enrollment target
Study Summary
This is a prospective, randomized, multicenter study to assess the tolerance of infant formulas.
Primary Outcome
Parent completed diary
Interventions
- OTHER Hydrolysate Infant Formula 1
- OTHER Hydrolysate Infant Formula 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2018-08-28 |
| Est. Completion | 2018-11-23 |
| Phase | NA |
What the finished NCT03628183 record still lists
NCT03628183 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Hydrolysate Infant Formula 1 is the first listed.
NCT03628183 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03628183 about?
NCT03628183 is a clinical study titled "Tolerance of Infants Fed a Hydrolysate Formula". This is a prospective, randomized, multicenter study to assess the tolerance of infant formulas.
What is the current status of trial NCT03628183?
This trial is currently completed. It is a NA study. The enrollment target is 51 participants. The study started on 2018-08-28. Estimated completion is 2018-11-23.
What interventions are being tested in trial NCT03628183?
The interventions under investigation include: Hydrolysate Infant Formula 1 (OTHER), Hydrolysate Infant Formula 2 (OTHER).
Who is sponsoring clinical trial NCT03628183?
This trial is sponsored by Abbott Nutrition, which has 89 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03628183's enrollment target sits among peer trials
51 1279th of 2000 higher than 722 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI